Abhishek A Mangaonkar1, Alejandro Ferrer2, Filippo Pinto E Vairo2, Margot A Cousin2, Ryan J Kuisle3, Naseema Gangat1, William J Hogan1, Mark R Litzow1, Tammy M McAllister3, Eric W Klee3, Konstantinos N Lazaridis4, A Keith Stewart5, Mrinal M Patnaik6. 1. Division of Hematology, Mayo Clinic, Rochester, Minnesota. 2. Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota. 4. Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota. 5. Division of Hematology, Mayo Clinic, Rochester, Minnesota; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota. 6. Division of Hematology, Mayo Clinic, Rochester, Minnesota. Electronic address: patnaik.mrinal@mayo.edu.
Abstract
OBJECTIVE: To demonstrate experience and feasibility of a precision medicine approach for patients with unexplained cytopenias, defined as low blood counts in one or more cell lineages, persistent for 6 months or longer, in the absence of known nutritional, autoimmune, infectious, toxic, and neoplastic (secondary) causes. PATIENTS AND METHODS: Patients were evaluated in our clinic between November 8, 2016, and January 12, 2018. After a thorough evaluation of known causes, family history, and appropriate clinical assays, genomic evaluation was performed in a stepwise manner, through Sanger, targeted, and/or whole-exome sequencing. Variants were analyzed and discussed in a genomics tumor board attended by clinicians, bioinformaticians, and molecular biologists. RESULTS: Sixty-eight patients were evaluated in our clinic. After genomic interrogation, they were classified into inherited bone marrow failure syndromes (IBMFS) (n=24, 35%), cytopenias without a known clinical syndrome which included idiopathic and clonal cytopenias of undetermined significance (CCUS) (n=30, 44%), and patients who did not fit into the above two categories ("others," n=14, 21%). A significant family history was found in only 17 (25%) patients (9 IBMFS, 2 CCUS, and 6 others), whereas gene variants were found in 43 (63%) patients (34 [79%] pathogenic including 12 IBMFS, 17 CCUS, and 5 others]. Genomic assessment resulted in a change in clinical management in 17 (25%) patients, as evidenced by changes in decisions with regards to therapeutic interventions (n=8, 47%), donor choice (n=6, 35%), and/or choice of conditioning regimen for hematopoietic stem cell transplantation (n=8, 47%). CONCLUSION: We show clinical utility of a real-world algorithmic precision medicine approach for unexplained cytopenias.
OBJECTIVE: To demonstrate experience and feasibility of a precision medicine approach for patients with unexplained cytopenias, defined as low blood counts in one or more cell lineages, persistent for 6 months or longer, in the absence of known nutritional, autoimmune, infectious, toxic, and neoplastic (secondary) causes. PATIENTS AND METHODS: Patients were evaluated in our clinic between November 8, 2016, and January 12, 2018. After a thorough evaluation of known causes, family history, and appropriate clinical assays, genomic evaluation was performed in a stepwise manner, through Sanger, targeted, and/or whole-exome sequencing. Variants were analyzed and discussed in a genomics tumor board attended by clinicians, bioinformaticians, and molecular biologists. RESULTS: Sixty-eight patients were evaluated in our clinic. After genomic interrogation, they were classified into inherited bone marrow failure syndromes (IBMFS) (n=24, 35%), cytopenias without a known clinical syndrome which included idiopathic and clonal cytopenias of undetermined significance (CCUS) (n=30, 44%), and patients who did not fit into the above two categories ("others," n=14, 21%). A significant family history was found in only 17 (25%) patients (9 IBMFS, 2 CCUS, and 6 others), whereas gene variants were found in 43 (63%) patients (34 [79%] pathogenic including 12 IBMFS, 17 CCUS, and 5 others]. Genomic assessment resulted in a change in clinical management in 17 (25%) patients, as evidenced by changes in decisions with regards to therapeutic interventions (n=8, 47%), donor choice (n=6, 35%), and/or choice of conditioning regimen for hematopoietic stem cell transplantation (n=8, 47%). CONCLUSION: We show clinical utility of a real-world algorithmic precision medicine approach for unexplained cytopenias.
Authors: Santhosh Dhanraj; Anna Matveev; Hongbing Li; Supanun Lauhasurayotin; Lawrence Jardine; Michaela Cada; Bozana Zlateska; Chetankumar S Tailor; Joseph Zhou; Roberto Mendoza-Londono; Ajoy Vincent; Peter R Durie; Stephen W Scherer; Johanna M Rommens; Elise Heon; Yigal Dror Journal: Blood Date: 2017-01-06 Impact factor: 22.113
Authors: Tania M Gonzalez Santiago; Andrey Zavialov; Janna Saarela; Mikko Seppanen; Ann M Reed; Roshini S Abraham; Lawrence E Gibson Journal: JAMA Dermatol Date: 2015-11 Impact factor: 10.282
Authors: Abhishek A Mangaonkar; Alejandro Ferrer; Filippo Pinto E Vairo; Margot A Cousin; Ryan J Kuisle; Eric W Klee; Cassie C Kennedy; Steve G Peters; J P Scott; James P Utz; Misbah Baqir; Hiroshi Sekiguchi; Shakila P Khan; Vilmarie Rodriguez; Douglas A Simonetto; Patrick S Kamath; Roshini S Abraham; Mark E Wylam; Mrinal M Patnaik Journal: Mayo Clin Proc Date: 2018-07 Impact factor: 7.616
Authors: Amy P Hsu; Kirby D Johnson; E Liana Falcone; Rajendran Sanalkumar; Lauren Sanchez; Dennis D Hickstein; Jennifer Cuellar-Rodriguez; Jacob E Lemieux; Christa S Zerbe; Emery H Bresnick; Steven M Holland Journal: Blood Date: 2013-03-15 Impact factor: 22.113
Authors: Michael A Spinner; Lauren A Sanchez; Amy P Hsu; Pamela A Shaw; Christa S Zerbe; Katherine R Calvo; Diane C Arthur; Wenjuan Gu; Christine M Gould; Carmen C Brewer; Edward W Cowen; Alexandra F Freeman; Kenneth N Olivier; Gulbu Uzel; Adrian M Zelazny; Janine R Daub; Christine D Spalding; Reginald J Claypool; Neelam K Giri; Blanche P Alter; Emily M Mace; Jordan S Orange; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Steven M Holland Journal: Blood Date: 2013-11-13 Impact factor: 22.113
Authors: Laura Schultz-Rogers; Francis P Lach; Kimberly A Rickman; Alejandro Ferrer; Abhishek A Mangaonkar; Tanya L Schwab; Christopher T Schmitz; Karl J Clark; Nikita R Dsouza; Michael T Zimmermann; Mark Litzow; Nicole Jacobi; Eric W Klee; Agata Smogorzewska; Mrinal M Patnaik Journal: Haematologica Date: 2021-04-01 Impact factor: 9.941
Authors: Naomi Alpert; Joseph L Rapp; John Mascarenhas; Eileen Scigliano; Douglas Tremblay; Bridget K Marcellino; Emanuela Taioli Journal: Front Oncol Date: 2020-11-20 Impact factor: 6.244
Authors: Abhishek A Mangaonkar; Alejandro Ferrer; Filippo Pinto E Vairo; Caleb W Hammel; Carri Prochnow; Naseema Gangat; William J Hogan; Mark R Litzow; Steve G Peters; J P Scott; James P Utz; Misbah Baqir; Eva M Carmona-Porquera; Sanjay Kalra; Hiroshi Sekiguchi; Shakila P Khan; Douglas A Simonetto; Eric W Klee; Patrick S Kamath; Anja C Roden; Avni Y Joshi; Cassie C Kennedy; Mark E Wylam; Mrinal M Patnaik Journal: Blood Cancer J Date: 2021-10-22 Impact factor: 11.037
Authors: Alejandro Ferrer; Abhishek A Mangaonkar; Susanna Stroik; Michael T Zimmermann; Ashley N Sigafoos; Patrick S Kamath; Douglas A Simonetto; Mark E Wylam; Eva M Carmona; Konstantinos N Lazaridis; Steve Peters; Keith Stewart; Eric W Klee; Eric A Hendrickson; Mrinal M Patnaik Journal: Blood Cancer J Date: 2020-11-17 Impact factor: 11.037